LAG3 and head and neck squamous cell carcinoma: Eftilagimod alpha, a soluble LAG-3 protein, combined with pembrolizumab, showed a 29.7% ORR in PD-L1-negative first-line R/M HNSCC, offering a chemotherapy-free option for a high-unmet-need group [119].